|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2008-5-2
|
|
pubmed:abstractText |
Deforolimus (AP23573), a novel non-prodrug rapamycin analogue, inhibits the mammalian target of rapamycin, a downstream effector of the phosphatidylinositol 3-kinase/Akt and nutrient-sensing pathways. A phase 2 trial was conducted to determine the efficacy and safety of single-agent deforolimus in patients with relapsed or refractory hematologic malignancies.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2756-62
|
|
pubmed:dateRevised |
2009-9-7
|
|
pubmed:meshHeading |
pubmed-meshheading:18451242-Adult,
pubmed-meshheading:18451242-Aged,
pubmed-meshheading:18451242-Aged, 80 and over,
pubmed-meshheading:18451242-Antineoplastic Agents,
pubmed-meshheading:18451242-Cohort Studies,
pubmed-meshheading:18451242-Female,
pubmed-meshheading:18451242-Hematologic Neoplasms,
pubmed-meshheading:18451242-Humans,
pubmed-meshheading:18451242-Male,
pubmed-meshheading:18451242-Middle Aged,
pubmed-meshheading:18451242-Sirolimus,
pubmed-meshheading:18451242-Vascular Endothelial Growth Factor A
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.
|
|
pubmed:affiliation |
Duke University Medical Center, Durham, North Carolina 27710, USA. rizzi003@mc.duke.edu
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study,
Clinical Trial, Phase II
|
